Kura Oncology, Inc. (KURA) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.3x

Market Cap

$1.17B

MomentumView details →

1D Return

+0.16%

YTD Return

+25.51%

RSI (14)

63.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.3x

Market Cap

$1.17B

RSI (14)

63.9

MomentumView details →

1D Return

+0.16%

YTD Return

+25.51%

SummaryUpdated Jun 1, 2026

Kura Oncology, Inc. (NASDAQ:KURA) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in San Diego, California. The company went public in September 2015 and focuses on developing precision medicines for cancer treatment. Kura has built a pipeline of small molecule drug candidates designed to target specific genetic mutations and pathways involved in various cancers, with its lead programs showing particular promise in blood cancers like acute myeloid leukemia (AML) and solid tumors including gastrointestinal stromal tumors (GIST).

Ask drillr about Kura Oncology, Inc. →

ProfitabilityView details →

Gross Margin

94.73%

Net Margin

−384.30%

EBITDA Margin

−378.60%

ROE (TTM)

−612.78%

ROA (TTM)

−50.49%

Asset Turnover

0.12x

GrowthView details →

Revenue YoY

−7.27%

EPS YoY

−49.12%

FCF YoY

—

Revenue CAGR 3Y

+25.24%

EPS CAGR 3Y

−57.43%

EBITDA YoY

−51.31%

EarningsView details →

EPS (Actual)

−$0.77

EPS Surprise

12.23%

Beats (12Q)

8/12

Next Q EPS Est

−$0.82

Avg Surprise (4Q)

−156.52%

Rev Surprise

3.53%

Capital & dividendView details →

Debt/Equity

0.50x

Current Ratio

4.73x

Quick Ratio

4.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

77.22M

Net Income (TTM)

−296.77M

Op. CF (TTM)

−111.76M

Next earningsNov 3, 2026 →

Latest newsMore news →

Kura Oncology's CEO Wilson purchased shares of the company, disclosed after hours, causing the stock to rise 9.84% to $13.62.10d ago

Kura Oncology reported its second quarter 2026 financial results, including $9.1 million in net product revenue from KOMZIFTI (ziftomenib), up 57% over the first quarter, and approximately 115 new patient starts, up 35% over the first quarter.23d ago

Similar companies

Monte Rosa Therapeutics, Inc.GLUE Attovia Therapeutics, Inc.ATTO Sana Biotechnology, Inc.SANA Inventiva S.A.IVA Corvus Pharmaceuticals, Inc.CRVS Janux Therapeutics, Inc.JANX Find similar companies →

Latest newsMore news →

Kura Oncology's CEO Wilson purchased shares of the company, disclosed after hours, causing the stock to rise 9.84% to $13.62.10d ago Kura Oncology reported its second quarter 2026 financial results, including $9.1 million in net product revenue from KOMZIFTI (ziftomenib), up 57% over the first quarter, and approximately 115 new patient starts, up 35% over the first quarter.23d ago